

CARDIFF AND VALE UNIVERSITY HEALTH BOARD
NOTES OF THE MEDICINES MANAGEMENT GROUP MEETING
HELD ON THURSDAY 25th APRIL 2013

Present: [REDACTED]

ACTION

1. Apologies

[REDACTED]

2. Declarations of interest

None

3. Minutes of last meeting – 2nd April 2013

Apologies from [REDACTED] were noted.

4. Matters arising

a) *Mental Health prescribing issues*

- Memantine prescribing

[REDACTED] will chase [REDACTED] to ensure that an SBAR [REDACTED] is available for the May MMG meeting.

- ECG monitoring for patients on anti-psychotics

[REDACTED] (Mental Health Pharmacist) has drafted a document summarising the license requirements for a range of anti psychotics. This has been forwarded to Primary Care pharmacist [REDACTED]. This will be taken back to the Mental Health Medicines Management Group along with the associated questions around who undertakes the ECG recording, interprets it and takes action where necessary.

b) *Guidelines for diagnosing and treating Vitamin D deficiency*

[REDACTED] confirmed that at the end of the Health Start Vitamins pilot i.e. from 1st April 2013 only women and children who qualify will receive healthy start vitamins. To qualify for Healthy Start the women must be:

At least 10 weeks pregnant or have a child under four years old **and** the woman or her family get:

- Income support, or
- Income bases Jobseekers Allowance, or
- Income related Employment and Support Allowance, or
- Child Tax Credit (but not Working Tax Credit unless the family is receiving Working Tax Credit run-on only*) **and** has an annual income of £16,190 or less (2013/14)

Women who are under 18 and pregnant will also qualify even if they do not get any of the above benefits or tax credits.

[REDACTED] will be asked to complete the guidelines which will be signed off by the chair without returning to MMG meeting. The formulary implications noted by [REDACTED] will need to be picked up at the next D&TC meeting on 23rd May [REDACTED]

It was noted that the National Osteoporosis Society Vitamin D and Bone Health: A Practical Guideline for Patient Management, was published the previous day.

c) *Shared Care prescribing of anti alzheimers drugs*

■ reported that a meeting is being held on 1st May to agree a way forward and will update the group at the next meeting.

d) *Safe sedation – Guidelines for clinical staff*

■ has forwarded the comments from MMG to ■ and arranged to meet her to agree the final version.

e) *Recommendations / suggestions with regard to safety issues using sedation in the cardiac suite for invasive procedures*

Following discussion it was agreed that this is a local issue for the Cardiac Directorate and will be referred to their Q&S meeting.

5. Operational plan

a) *Financial planning: Medicines management savings 2012 - 13*

■ noted there were no changes to the savings plan tabled at the last meeting. It was noted that Ernst & Young were leading the development of the project outline document (POD). This will support the delivery of medicines management savings across the UHB, responsibility for which will sit within the O4E Leaner and Fitter workstream. The POD will be shared when finalised.

6. NICE/AWMSG implementation

a) *IPD – Tapentadol – Update*

■ updated the group on the ongoing discussion between the chronic pain team and primary care. Conclusion to be provided next month.

7. Management of medicines across the healthcare community

a) *Drug Tariff – Appliances*

■ noted several recent changes to the Drug Tariff and the recommendation of products by secondary care for GP prescription. This has included a pelvic floor device recommended by physiotherapy and a jaw stabiliser by speech and language therapy. It was agreed that the terms of reference of the D&TC should be considered at its next meeting. It was agreed in the interim that such products should be treated as “non-formulary” and ■ will respond to that effect (providing a copy of the D&TC application form).

It was also noted that a number of “pharmaceuticals” were available through Oracle without the level of challenge that would be provided by Pharmacy. ■ agreed to raise with ■ as part of the UHB Procurement “Better value supply chain” workstream.

b) *Out of area shared care requests*

The shared care sub-group of DTC met on 19th Feb 2013 and following contact with WHSSC suggested that initial communication should be between the transplant/tertiary centre e.g. outside Wales,

and the secondary care team who referred the patient. The secondary care team will then enter into a local shared care arrangement with the relevant GP. This was supported by MMG and will need to be communicated in next Prescribing newsletter.

8. Items for approval

a) Drug & Therapeutics Committee 14 March 13 – minutes and recommendations
See appendix

b) Standard Operating Procedure - Ensuring patients' are prescribed the most cost effective once daily prolonged release preparation of isosorbide mononitrate 60mg
The SOP was approved.

9. Items to note

None.

10. Any other business

requested an update on the medicines waste campaign. indicated that a meeting was scheduled for early May and would provide a briefing for the next meeting.

12. Date of next meeting

2.00 – 4.00 on 21st May, Council Room, UHW

NotesMMG/s:lg/MMG
25April2013

Formulary decisions - Bro Taf Localities DTC meeting 14 March 2013

Product	Outcome	BNF section	C&V decisions
FORMULARY APPLICATIONS			
Bimatoprost (Lumigan®) 0.03% Unit Dose Allergan Ltd	Bimatoprost UDV is recommended for addition to the Formulary as a Specialist Initiated item.	11.6	Agreed
Atorvastatin (Lipitor®) Chewable tablets Pfizer Ltd	Atorvastatin chewable tablets to be approved specifically for use in patients who are being swapped from simvastatin liquid. The chewable tablets will be Second Line.	2.12	Wording change: Atorvastatin chewable tablets- Second line (restricted to patients in whom simvastatin liquid is being considered)
FORMULARY REPORT			
Sustanon	Request from Cwm Taf Pharmacy - Remove from formulary	6.4.2	Not agreed (leave)
Yasmin	Request from Cwm Taf Pharmacy - Remove from formulary	7.3.1	Agreed
Riboflavine	NICE Sept 2012 Unlicensed product – not to be added to formulary		Agreed
FORMULARY REVIEW			
Promethazine HCl oral and injection	Add to the Formulary Second Line	Chapter 4 3.4.1 4.6	Agreed
Loprazolam	Not to be added to the formulary	Chapter 4	Agreed
Temazepam	Annotate as Second Line	4.1.1	Agreed
nitrazepam	Remove from the Formulary	4.1.1	Agreed
Zolpidem	Not to be added to the Formulary	Chapter 4	Agreed
Buspirone 10mg tablets	Not to be added to the Formulary	Chapter 4	Agreed
Cefuroxime oral	Add for C&V only.		Check with AMG
Tigecycline	Remove from Formulary	5.1.3	Check with AMG
Parecoxib	C&V remove. Cwm Taf – use to be reviewed.	10.1.1	Agreed
Tamsulosin, dutasteride and finasteride	Request from Cwm Taf pharmacy- Status of finasteride to be changed from Specialist Initiated. Further information to be sought outside the meeting regarding appropriate category for these drugs.		
Mesalazine Octasa MR 400mg and 800mg tablets	Request from Cwm Taf pharmacy- Add as Specialist Initiated	1.5	No agreed (C&V review underway)
Clobazam liquid	Request from C&V pharmacy SMPU to stop manufacturing	4.1.2?	Agreed

Product	Outcome	BNF section	C&V decisions
	the special. Licensed product to be purchased for existing patients until such time as it is reviewed by AWMSG. (?Tapclob oral suspension?)		
NICE			
Mannitol dry powder	TA266 Nov 12 C&V MMG have already agreed Specialist Initiated following IPD. For further discussion in Cwm Taf	3.7	Agreed
Ivabradine	TA267 Nov 12 Remain Second Line	2.6.3	Agreed
Ipilimumab	TA268 Dec 12 Add Hospital Only	8.1.5	Agreed
Vemurafenib	TA269 Dec 12 Add Hospital Only	8.1.5	Agreed
Ranibizumab	TA274 Feb 13 Already in formulary for ARMD - Hospital Only	11.8.2	Agreed
Apixaban	TA275 Feb 13 For further discussion by C&V MMG who are awaiting an IPD and also by Cwm Taf MMEC who are reviewing their guidelines.	2.8.2	C&V IPD awaited
AWMSG			
Degarelix (Firmagon®)	Advice No <u>4112</u> Nov 12 C&V have already agreed Hospital only following IPD Cwm Taf decision awaited	8.3.4	Agreed
Fidaxomicin (Dificlor®▼)	Advice No <u>3712</u> Nov 12 C&V - await IPD and discussion at MMG Cwm Taf - decision awaited	5.1.7	C&V IPD awaited
Insulin detemir (Levemir®)	Advice No <u>3912</u> Nov 12 Change to Specialist Recommended	6.1.1	Agreed
Eplerenone (Inspra®▼)	Advice No <u>2712</u> Dec 12 Already in as Specialist Initiated	2.2.3	Agreed
Sildenafil citrate (Revatio®▼)	Advice No <u>4012</u> Dec 12 Already in formulary for Cwm Taf C&V – add as Specialist Initiated	2.5.1	Agreed
Argatroban (Exembol®)	Advice No <u>4312</u> Dec 12 Hospital Only	2.8.1	Agreed
Bortezomib (Velcade®▼)	Advice No <u>3812</u> Dec 12 Already in as Hospital only	8.1.5	Agreed

